Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) announced its plan to conduct an underwritten public offering of common stock and warrants, subject to market conditions. The company aims to use the net proceeds for the commercialization of NEXLETOL and NEXLIZET, along with research and development for its pipeline. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering. The offering is subject to various conditions, with no guarantee on its completion or terms. A registration statement has been filed with the SEC, and additional details will be available in a related prospectus.
Esperion announced significant findings from three abstracts on NEXLETOL (bempedoic acid) presented at the AHA Scientific Sessions 2021. Data from pooled Phase 3 studies showed that NEXLETOL effectively lowers LDL-C levels, achieving a ≥30% reduction comparable to high-intensity statins in nearly 1 in 3 patients. In individuals with metabolic syndrome, the treatment resulted in reductions in HbA1c and fasting plasma glucose. Notably, over 50% of patients not on background statins achieved significant LDL-C lowering. This establishes NEXLETOL's role in lipid management.
Esperion (NASDAQ: ESPR) announced a strategic plan to optimize its operational and expense structure, aiming for long-term growth in its lipid management products, NEXLETOL and NEXLIZET. For Q3 2021, U.S. net product revenue reached $10.9 million, driven by a 10% increase in prescriptions, with over 59,200 patients treated. The company reported total revenues of $14.4 million for the quarter, a significant rise from $3.8 million in Q3 2020. Research and development expenses decreased to $25.3 million, while net losses were $69.4 million. Looking ahead, the CLEAR Outcomes study remains on track for completion in 2H 2022.
Esperion (NASDAQ: ESPR) announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 from November 13-15, 2021. The highlighted studies include:
- Factors Associated with Enhanced LDL Cholesterol Lowering during Phase 3 studies of Bempedoic Acid.
- Efficacy and Safety of Bempedoic Acid in patients with Metabolic Syndrome.
- Pharmacokinetics and Safety of Bempedoic Acid in phase 1 trials.
Bempedoic Acid is indicated for adults requiring additional LDL-C lowering.
Esperion announced the appointment of Seth H.Z. Fischer as a Class III director, with his term expiring at the 2022 stockholders' meeting. His extensive experience in the pharmaceutical industry is expected to aid the company during this transformative period, particularly ahead of the CLEAR Outcomes trial results. Fischer's background includes leadership roles at various pharmaceutical companies, focusing on product growth and market strategies. Esperion aims to enhance access to its cholesterol-lowering oral medications for patients in need.
Esperion (NASDAQ: ESPR) announced participation in the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021. Members of the management team will engage in a fireside chat and 1:1 meetings, scheduled for 4:20 p.m. ET.
Live audio webcasts can be accessed via the Esperion website.
Replays will be available for 90 days after the events.
Esperion (NASDAQ: ESPR) announced a privately negotiated exchange agreement with two holders of its 4.00% Convertible Senior Subordinated Notes due 2025, exchanging $15 million of notes for common stock. The exchange will close on November 3, 2021, subject to conditions, with share issuance based on a volume-weighted average price floor of $5.62. This move aims to reduce cash interest expenses and improve the company’s balance sheet as it anticipates upcoming study results.
Esperion (NASDAQ: ESPR) announced a significant restructuring, reducing its workforce by 40% to enhance operational efficiency in response to challenges posed by the COVID-19 pandemic. This move aims to better support the company's growth strategy for its cholesterol medications, NEXLETOL and NEXLIZET, while focusing on a digital marketing approach. Esperion projects annualized cash savings of at least $80 million and has revised its operating expenses for FY 2021, estimating a reduction of $20 million from previous guidance, alongside a preliminary net product revenue of $10.5 to $11 million for Q3 2021.
Esperion (NASDAQ: ESPR) will report its third-quarter 2021 financial results on November 2, 2021, prior to the U.S. market opening. Following the earnings release, a webcast and conference call will be held at 8:00 a.m. ET to discuss the results and business developments. Investors can join the call by dialing (877) 831-3840 for domestic calls or (253) 237-1184 for international participants. The call will also be available via a live audio webcast on the company's investor section of their website.
Esperion (NASDAQ: ESPR) has announced an investor webinar scheduled for September 13, 2021, at 1:30 PM ET, focusing on elevated cholesterol treatment during National Cholesterol Awareness Month. The event will feature Dr. Steven Nissen, a leading cardiologist from the Cleveland Clinic, discussing current treatment paradigms, guidelines, and the importance of cardiovascular outcomes trials. The format includes an educational dialogue with Esperion's new Chief Medical Officer, Dr. JoAnne Foody, followed by a Q&A session. Registration is limited to investors.